The regulation of interleukin 1 receptor (IL 1 R) expression on human dermal fibroblasts was investigated. On exposure to IL 1 for 3 h at 370C, the capacity of fibroblasts to bind '25I-labeled human recombinant IL 1 alpha ('25I-IL la) was reduced by 75%. The IL 1 binding capability of the fibroblasts was restored to control levels by 16 h after removal of unbound IL 1, and then increased to about twofold over that of control cells by 48 h. This later enhancement of IL 1 receptor expression after IL 1 treatment was abolished by indomethacin. Addition of exogenous (PGEj and PGE2, also analogues of AMP, or forskolin increased the specific binding of 125I-IL la to fibroblasts. Scatchard analysis indicated that PGE2 increased the number of IL iR from -1.6 X 103 to 5.4 X 103 per cell without change in the binding affinity. These data suggest that the later IL 1-induced up-regulation of IL iR is mediated by IL 1 stimulation of endogenous prostaglandin production. The combination of PGE2 and prednisolone increased the number of IL iR on fibroblasts in an additive manner.
Introduction
The availability of recombinant murine and human IL 1 has facilitated studies of the cell surface receptor for IL 1 on various responsive cells. Dower et al. first reported the expression of specific receptors for IL 1 on a variety of both human and murine cell types (1) . We have also demonstrated the presence of high-affinity receptors for IL 1 on an EBV-transformed human B lymphocyte cell line and have shown that the receptors for IL la and IL I 3 are identical (2) . The regulation ofIL 1 receptor (IL-i R) expression on various cell types remains largely unexplored and provides a potentially crucial locus of control of IL 1 activity. We have reported that IL 1 rapidly down-regulates IL 1 receptor expression on the human large granular lymphocyte YT cell line (3) . We have also demonstrated that glucocorticoid hormones (GC) markedly increased the number of IL 1 receptors on several cell types including human peripheral B lymphocytes, human dermal fibroblasts, and YT cells without alteration in the binding affinity (4) .
In this study, we have similarly observed that IL 1 rapidly initially down-regulates IL 1 receptor expression on human dermal fibroblasts. However, thereafter, IL 1 up-regulates IL 1 receptor expression through IL-1-induced endogenous production of prostaglandin(s) on human dermal fibroblasts. Exogenously added PGE2 and prednisolone also enhanced IL 1 R expression by fibroblasts and PBMC in an additive manner. Consequently, these data suggest that the in vivo expression of IL 1 receptors may be up-regulated both by prostaglandins and glucocorticoids that are produced in response to administration of IL 1.
Methods
Reagents. Prednisolone, PGE1, PGE2, 8-Bromoadenosine 3':5'-cyclic monophosphate (8-Br cAMP), N6,2'-O-dibutyryladenosine-3':5'-cyclic monophosphate (dibutyryl cAMP), N2,02'-dibutyryl guanosine-3':5'-cyclic monophosphoric acid (dibutyryl cGMP), and forskolin were purchased from Sigma Chemical Co. (St. Louis, MO). Cycloheximide (CH) and actinomycin D (Act. D) were also obtained from Sigma Chemical Co. Purified, carrier-free human recombinant IL-1 a was a generous gift from Dr. M. Yamada (Dainippon Pharmaceutical Co., Osaka, Japan).
Cell culture. Human dermal fibroblasts (CRL 1507; American Type Culture Collection, Rockville, MD) were maintained in DME (Advanced Biotechnologies Inc., Silver Spring, MD) supplemented with 10% FCS (Hyclone Laboratories, Logan, UT), 2 mM of L-glutamine, 100 U/ml penicillin, and 100 ,g/ml streptomycin at 370C in 5% CO2. Fibroblasts (7 X I05 cells; passages were plated in 35-mmdiam dishes (3506, Costar, Cambridge, MA) containing 3 ml of medium. After 2 d, the medium was replaced with 3 ml of new medium at 37'C containing various reagents as described. Prostaglandins were dissolved in 95% ethanol, forskolin was dissolved in DMSO, and cAMP was dissolved in Dulbecco's PBS and all were then added to the culture media to yield the indicated final concentration. An equivalent volume of ethanol or DMSO was added to control cultures. PBMC were freshly isolated by Ficoll-Hypaque gradient centrifugation and were resuspended at a density of 5 X 105 cells per ml in RPMI 1640 medium (Advanced Biotechnologies, Inc.) with 10% FCS.
Preparation of iodinated IL 1. Human recombinant IL 1 a was labeled with 1251 using the Bolton-Hunter reagent (2, 200 Ci/mmol, monoiodinated; New England Nuclear, Boston, MA) for 1 h on ice as previously described (4) . After stopping the reaction with 0.5 ml of 0.5 M glycine in 0.1 M borate buffer, pH 8.5, 1251I-IL la was separated from free iodine by chromatography on a Sephadex G-25 column (Pharmacia Fine Chemicals, Piscataway, NJ). The labeling efficiency of IL 1 was -5x 10X cpm of '251/4g of IL la.
Receptor binding assay. After treatment with various reagents, fibroblasts were transferred to 0.5 ml ofbinding medium (DME supplemented with I mg/ml BSA and 10 mM Hepes buffer). '25I-IL la (14 ng/ml) was incubated with cells in the presence or absence ofunlabeled IL 1 a at a concentration of 2 ug/ml. After a 1-h incubation at 4VC, the cells were rinsed four times with cold DME and solubilized in 0.5 ml of 0.1 N NaOH containing 2% Na2HCO3 and 1% SDS. The total cell-associated radioactivity was determined by counting this volume in a gamma counter. PBMC were harvested after treatment with various reagents, and the specific binding activity of I25I-IL Ila to PBMC was determined as described elsewhere (4) .
Measurement of PGE2 levels. PGE2 concentrations in culture media were determined by RIA using a PGE2 '251I-RIA kit (NEK 020A10; New England Nuclear).
Treatment with metabolic inhibitors. The cells were cultured with 3.5 ug/ml CH or 1.5 ug/ml Act. D in the presence of prednisolone (1 X 10-6 M) or PGE2 (1 X 10-6 M) or 8-Br cAMP (I X 10-3 M). After 12 h of culture, the effects of the metabolic inhibitor on the induction of IL 1 receptor were measured. The viability of the treated cells was not changed as compared with the control cells as measured by trypan blue dye exclusion test.
Results
Biphasic effects ofIL I on IL I receptor expression. We examined the effect of IL 1 on IL IR expression on normal human dermal fibroblasts. Fibroblasts in a confluent state were preincubated for 3 h at 370C in the presence or absence of human recombinant IL la (100 U/ml). The cells were washed extensively to remove unbound IL 1, and were subsequently incubated in fresh medium at 370C. Fig. 1 demonstrates the total binding of '25I-IL la to fibroblasts at different times after IL 1 treatment. Under these conditions, IL 1 initially down-regulated IL 1 R on the surface of fibroblasts as observed in a human large granular lymphocyte cell line, YT cells, and other cell types (3, 5) . In this study, pretreatment with 100 U/ml IL 1 (5 ng) reduced the binding of '25I-IL Ila to fibroblasts by 75%. The binding of labeled IL 1 recovered to -60% of control by 6 h, and returned to control levels by 16-20 h. IL 1-untreated control cells showed moderately reduced binding after 24 h of incubation. The binding of 125f-IL I1a to IL l-pretreated cells progressively increased over control levels with 24 and 116% increases over control level at 30 and 48 h, respectively, and returned to control levels by day 3. Because the enhancement of IL 1 binding occurred relatively slowly, it was hypothesized to be an indirect effect me- Table I , we also can demonstrate the production of PGE2 by fibroblasts in response to IL 1 and the block of PGE2 production by indomethacin. Under the condition of this experiment, the cell number and viability of down-regulated cells remained the same as for control cells ( Table 1 ). These data suggest that the later IL 1-induced upregulation of IL IR is mediated by endogenous production of prostaglandins. Effect ofprostaglandins on specific '25I-IL la binding.
Human dermal fibroblasts were exposed to PGE2 (1 X 10-6 M) to determine the effect of exogenously added POE on IL IR expression. IR on other cell types, PBMC were exposed to PGE2 or prednisolone for 6 h at 370C. Cells were subsequently harvested and the specific binding activity of '251I-IL I a was determined.
As shown in Table II (Fig. 6 ). These data suggest that prostaglandins-and GC-induced IL 1 R up-regulation required both protein and RNA synthesis. 
Discussion
Down-regulation of receptors by their ligands is commonly observed for hormones and cytokines including epidermal growth factor (EGF) (9), insulin (10), and IFN (11) . Rapid down-regulation of IL 1R expression by IL 1 has also been reported for the human LGL cell line YT (3), the murine T cell line, EL4, and the fibroblast cell line, Swiss 3T3, (5). We previously reported that a brief, 3-h incubation ofYT cells with IL 1 down-regulates IL 1R expression and IL 1 binding returns to normal levels by 16 h at 37°C after removal of IL 1 from the culture media. Similarly, exposure of normal human fibroblasts to IL 1 initially down-regulates IL 1R, and is followed by up-regulation of IL 1R expression. The phenomenon of ligand-dependent induction of specific receptors has been demonstrated to occur at the level oftranscription or at the protein level in the case of EGF (12, 13) , growth hormone (14) , prolactin (15), insulin (16), and IL 2 (17). On the other hand, the synthesis of the receptor for low density lipoprotein has been reported to be inhibited by ligand binding (18) . The basis for the effect of IL 1 on IL 1R gene expression remains to be established.
Many reports have demonstrated the regulatory role of cAMP on gene expression (19) (20) (21) (22) (23) . For example, forskolin and cAMP analogues enhanced the expression of low-and high-affinity IL 2 receptors on YT cells and T cell lines (24) . Both cAMP-dependent protein kinase (A-kinase) and calciumphospholipid dependent protein kinase (C-kinase) (25) can also activate IL 2R expression in the course of lymphocyte activation. However, phorbol esters, potent activators of C-kinase, could not modulate IL 1 R expression on fibroblasts, PBMC, and YT cells (data not shown), arguing against the involvement of C-kinase system in up-regulating IL 1 R expression. Since forskolin, a reversible activator of adenylate (4) . The induction of de novo synthesis of IL IR on B cells by GC is rather unexpected, because GC are well known to suppress both IL 1 production (26, 27) and effects of IL 1 on T cells (28) , which presumably contribute to the suppressive effects of GC on inflammation and immunity. However, it has also clearly documented that GC stimulates in vitro polyclonal immunoglobulin production by PBMC (29) , which may be based on the induction of functional IL IR on B cells (4) . These divergent effects ofGC led us to propose that GC may use this mechanism to favor humoral immunity at the expense of cell-mediated immunity (4) .
Prostaglandins appear to have analogous effects to GC on IL IR expression. PG induce two-to threefold increases in the expression of IL 1R on fibroblasts and sixfold increases on PBMC. However, prostaglandins, like GC, also suppress the production of IL 1 (30) , inhibit the effects of IL 1 on T lymphocytes (31), suppress Ia antigen expression of macrophages (26) , inhibit macrophage cytotoxicity (32) , and reduce cellular immune reactions. In contrast, conflicting data have been reported concerning the effect of PGE2 on B lymphocytes. Although prostaglandins suppress B cell proliferation (33) , both PGE2 and cAMP analogues were reported to be able to synergize effectively with IL 1 and IL 2 to induce B cell maturation and antibody production (34) . Thus, prostaglandins, by inducing IL I R on B lymphocytes, may also favor humoral immunity at the expense of cellular immunity.
The interactions of prostaglandins and IL 1 on fibroblasts are also complex. Prostaglandin mediates some ofthe effects of IL 1 on some cell types. For example, we have previously reported that the augmentation of human monocyte cytotoxicity by IL 1 is mediated by endogenous production of PGE (35) . IL 1 stimulation of plasminogen activator production by human synovial fibroblasts is also said to be mediated by endogenous PGE production (36) . In addition to mediating some of the effects of IL 1, PGE can also further promote the effects of IL 1 indirectly by inducing expression of IL 1 receptors on fibroblasts. The physiological role of IL 1 receptor induction on fibroblasts may be to promote wound healing.
Multiple interactions can potentially occur between IL 1, prostaglandins, and GC in vivo. Administration of IL 1 induces increased serum cortisol levels (37). IL 1 also induces the production of prostaglandins by many cell types (35) . Inhibition ofprostaglandin and IL 1 production by GC may counteract some of these effects. We have shown that both PGE and GC induce IL 1R expression by fibroblasts and PBMC. Since PGE and GC induce IL 1R expression in an additive manner and indomethacin did not block GC-induced IL 1R expression, the pathways are probably distinct. Overall, these data suggest that IL 1, prostaglandins, and GC can influence each others' production and effects in both an agonistic and antagonistic manner.
